Newron Pharmaceuticals S.p.A.
NP5
Ранг среди акций
#17693
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Цена акции
$10.40
Рыночная капитализация
$212.64M
Изменение (1 день)
1.09%
Изменение (1 год)
-41.83%
Страна
IT
Торговля Newron Pharmaceuticals S.p.A. (NP5)
Категория
Healthcare
История цены акций Newron Pharmaceuticals S.p.A. (NP5)
Наивысшая цена закрытия: $10.24 2026-10-01
Наименьшая цена закрытия: $31.91 2015-07-01
Наименьшая цена закрытия: $31.91 2015-07-01
История цены акций Newron Pharmaceuticals S.p.A. с 2015 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | -24.57% |
| 2025 | 182.46% |
| 2024 | 72.12% |
| 2023 | 283.57% |
| 2022 | -24.03% |
| 2021 | -24.86% |
| 2020 | -62.21% |
| 2019 | -18.66% |
| 2018 | -28.88% |
| 2017 | -55.22% |
| 2016 | -5.77% |
| 2015 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $534.84 | 25.42% |
US
|
|
| $189.00 | 603.91% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $888.12 | 9.08% |
NL
|
